(Q33377626)
Statements
1 reference
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study (English)
1 reference
Shanu Modi
1 reference
Alison T Stopeck
1 reference
Michael S Gordon
1 reference
David Mendelson
1 reference
David B Solit
1 reference
Rochelle Bagatell
1 reference
Jennifer Wheler
1 reference
Neal Rosen
1 reference
Gillian F Cropp
1 reference
Robert G Johnson
1 reference
Alison L Hannah
1 reference
Clifford A Hudis
1 reference
1 December 2007
1 reference
1 reference
25
1 reference
34
1 reference
5410-5417
1 reference
Identifiers
1 reference
1 reference